Bombesin analogues for gastrin-releasing peptide receptor imaging

Nuclear Medicine and Biology

Volumn 39, Issue 4, 2012, Pages 461-471

  Nanda, Prasant K ^a   Pandey, Usha ^a   Bottenus, Brienne N ^b   Rold, Tammy L ^a   Sieckman, Gary L ^c   Szczodroski, Ashley F ^c   Hoffman, Timothy J ^a,b,c   Smith, Charles J ^a,b,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

64Cu; Antagonist; Bombesin (BBN); Gastrin releasing peptide receptor (GRPR); Positron emission tomography (PET)

Indexed keywords

BOMBESIN DERIVATIVE; COPPER 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID 6 AMINO HEXANOIC ACID BOMBESIN[6-13][6 DEXTRO PHENYLALANINE]ETHYLAMIDE CU 64; COPPER 1,4,7 TRIAZACYCLONONANE 1,4 DIACETIC ACID 9 AMINONONANOIC ACID BOMBESIN[6-13][6 DEXTRO PHENYLALANINE]ETHYLAMIDE CU 64; GASTRIN RELEASING PEPTIDE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; BIOACCUMULATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOISOTOPE DISTRIBUTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR SCINTISCANNING; URINARY EXCRETION;

ANIMALS; BINDING, COMPETITIVE; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, BOMBESIN; X-RAY MICROTOMOGRAPHY;

EID: 84862819921     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.10.009     Document Type: Article

References (35)

1. Krenning E.P., De Jong M. Therapeutic use of radiolabelled peptides. Ann Oncol 2000, 11:267-271.
2. Krenning E.P., Kwekkeboom D.J., Valkema R., Pauwels S., Kvols L.K., De Jong M. Peptide receptor imaging and therapy. Ann N Y Acad Sci 2004, 1014:234-245.
3. Blum J.E., Handmaker H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr Pharm Des 2002, 8:1815-1826.
4. Behr T.M., Gotthardt M., Barth A., Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001, 45:189-200.
5. Signore A., Annovazzi A., Chianelli M., Corsetti F., Van de Wiele C., Watherhouse R.N. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001, 28:1555-1565.
6. Okarvi S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001, 28:929-938.
7. Smith C.J., Volkert W.A., Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 2005, 32:733-740.
8. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
9. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999, 99:2235-2268.
10. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Nat Acad Sci USA 2007, 104:12462-12467.
11. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
12. Cancer facts and figures 2010 2010, American Cancer Society, American Cancer Society, Atlanta.
13. Sun B., Halmos G., Schally A.V., Wang X., Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000, 42:295-303.
14. 2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009, 36:171-181.
15. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007, 13:3-16.
16. Hoffman T.J., Smith C.J. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol 2009, 36:579-585.
17. Nijsen J.F., Krijger G.C., van Het Schip A.D. The bright future of radionuclides for cancer therapy. Anti-Cancer Agents Med Chem 2007, 7:271-290.
18. Anderson C.J., Welch M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999, 99:2219-2234.
19. Blower P.J., Lewis J.S., Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996, 23:957-980.
20. Bodei L., Paganelli G., Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006, 47:375-377.
21. Koenig J.A., Edwardson J.M. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 1997, 18:276-287.
22. Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006, 47:502-511.
23. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006, 103:16436-16441.
24. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
25. Lister-James J., Moyer B.R., Dean R.T. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 1997, 41:111-118.
26. Arano Y. Strategies to reduce renal radioactivity levels of antibody fragments. Q J Nucl Med 1998, 42:262-270.
27. Abd-Elgaliel W.R., Gallazzi F., Garrison J.C., Rold T.L., Sieckman G.L., Figueroa S.D., et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjugate Chem 2008, 19:2040-2048.
28. 2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010, 37:751-761.
29. 99mTc demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30:247-258.
30. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M.L., Waser B., et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009, 15:5240-5249.
31. Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
32. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
33. Vauquelin G., Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006, 27:356-359.
34. Pelosi G., Volante M., Papotti M., Sonzogni A., Masullo M., Viale G. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging 2006, 50:272-287.
35. Gonzalez N., Moody T.W., Igarashi H., Ito T., Jensen R.T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 2008, 15:58-64.